DERM
Journey Medical Corp
$7.12
+0.26 (+3.79%)
At close · Jul 14
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$196.05M
Shares
27,534,547
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.12
Open$6.92
Day$6.75–7.21
52W$4.31–9.56
Avg vol 30d301K
Short int3.0M · 10.9% float · 5.3d
Short vol19%
Last earningsMay 13, 2026
DataNov 2021–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
+15%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
54%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−18%
trailing
YTD return
−8%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
4 of 71 funds reported for Jun 30 · net +740.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.86% of float · ▼ -14.9% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
EPS growth
+35%
Y/Y
Balance sheet
$1.2M
net debt
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
54%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
4 of 71 funds reported for Jun 30 · net +740.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.86% of float · ▼ -14.9% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $7 · 54%
52-wk high $10
vs 200-day avg +0%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA per share basic and diluted non-GAAP | $0.02 | first quarter of 2026 | — |
| adjusted EBITDA non-GAAP | $600,000 | Q1 2026 call | — |
| adjusted EBITDA per share non-GAAP | $0.02 | Q1 2026 call | — |
| commercial lives with access to EMROSI | 169M | Q1 2026 call | — |
| MROSI prescriptions | 30,000 | Q1 2026 call | — |
| refill-to-new prescription ratio | 1.5 | Q1 2026 call | — |
| unique dermatology prescribers | 3,700 | Q1 2026 call | — |
| Adjusted EBITDA per share basic non-GAAP | $0.12 | full year 2025 | — |
| Emrosi™ net revenues | $14.7M | full-year 2025 | — |
| Payer access for Emrosi™ (U.S. commercial lives) | 100M | July 2025 | — |
| Total prescriptions filled for Emrosi™ | 53,000 | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DERM
this stock
Journey Medical Corp
|
$196.05M | -7.7% | +10.2% | — | 10.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.34B | +5.1% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$49.01B | +0.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.72B | -4.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DERM | +5.6% | +12.3% | -18.4% | +0.6% | -7.7% |
| SPY | +0.6% | +1.4% | +11.0% | +0.7% | +10.3% |
| vs SPY | +5.0% | +10.9% | -29.4% | -0.1% | -17.9% |